Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities
Time: 4:50 pm
day: Day One
Details:
- Examining what we do and do not know about the aging process
- Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions
- Analyzing the current R&D landscape for anti-aging therapeutics
- Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date and perspectives on future directions
Speakers:
Samuel Agus serves as Chief Medical Officer for Biophytis, a company that specializes in aging sciences, since July 2018. Prior to that, he served at various leadership positions in clinical development and medical affairs, in pharmaceutical and biotech companies, such as Teva Pharmaceuticals industries, Solvay Pharmaceuticals, Abbott, Shire, H. Lundbeck A/S. and Hansa Biopharma. Dr.…Read more
A native of Scotland, Dr. Lithgow received his PhD from the University of Glasgow and obtained further training at Ciba Geigy AG in Basel, Switzerland, and at the University of Colorado. He established his lab studying the biology of aging at the University of Manchester, England, before moving it to the Buck Institute in 2000.…Read more
Adam is a Principal Investigator at Calico Life Sciences, a Google-backed biotechnology company focused on aging and age-related diseases, with the goal of developing interventions that enable people to live longer and healthier lives. Adam’s lab works to identify and test post-developmental interventions that slow or reverse aspects of aging. This requires robust assays to…Read more
Dr. Shandler brings nearly a decade of various commercial and scientific operating experiences to Longevity. Prior to founding Longevity, Dr. Shandler was a venture capitalist at BioAdvance, an early stage fund based in Philadelphia, where he was responsible for therapeutics, diagnostic and biomarker opportunities. Prior to BioAdvance, Dr. Shandler was a portfolio analyst for Merck…Read more
Lewis S. Gruber is the co-founder and CEO of SIWA Therapeutics, Inc. Prior to SIWA, he was interim CEO of a company developing a natural killer cell line product; he resigned to found SIWA. He also co-founded and was CEO of Arryx, Inc. (acquired by a publicly-held company). While CEO, Arryx received awards including World…Read more
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing…Read more
Over 15 years’ experience in a fast-track career, from premier research institutions to co-founding biotech and venture capital firms. Co-founded 5 biotech companies in Europe and the US. Currently, He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He is…Read more
Marco co-founded Rubedo Life Sciences, with the company’s mission aimed to increase healthspan by treating the causes of age-related diseases. The strategy is based on systemic therapies capable of safely targeting across the body specific cell types, such as senescent cells, stem cells or cancer cells. Marco also co-founded Wetware Concepts, YEBN and Turn Biotechnology.…Read more